The research team undertook a systematic document analysis of every national clinical practice guideline developed by the Colombian Ministry of Health — 58 in total, produced between 2008 and 2016 — together with all 14 health systems guidance documents published by the World Health Organization. Searches were conducted between December 2019 and April 2020, with two team members working independently to retrieve the most current versions of each document. From the Colombian guidelines, which collectively contain roughly 3,500 recommendations, the researchers focused on those explicitly flagged by their development groups as key, priority, or tracer recommendations — those judged to carry the greatest potential impact on patient outcomes or on the health system itself. Where no such prioritization existed, the team contacted the guideline development group leaders directly to obtain it. All 363 recommendations from the WHO health systems guidance were included, on the rationale that supranational guidance inherently contains priority recommendations and that Colombia’s government has formally committed to receiving WHO advice.

The unit of analysis throughout was the individual recommendation, and the extraction protocol was deliberately granular. For each recommendation, the team recorded the parent guideline’s characteristics, the recommendation’s full text, its strength as graded by the original development group — whether through letter grades A through D or the GRADE system, which assesses the certainty of the underlying evidence and the likelihood that all informed patients would choose the intervention — and its direction, meaning whether it favored or argued against an intervention. Recommendations graded A, B, or strong were pooled as strong; those graded C, D, or weak were treated as weak; conditional recommendations formed a third category. The team also logged the type of technology or service addressed — medication, diagnostic test, device, procedure, counseling, or education — and the currency of the evidence, classifying recommendations as updated if published or revised within the previous four years, close to outdated in their fifth year, and outdated beyond that. A pilot extraction of 50 recommendations was used to calibrate the team before the full dataset was compiled, with all extraction performed independently in duplicate and discrepancies resolved by consensus or third-party adjudication.

The numbers that emerged are striking. Across the 71 guidelines analyzed, 958 prioritized recommendations were identified: 595 from the Colombian guidelines and 363 from the WHO documents. Of these, only 393 — 41 percent — were current, while 425 (44.4 percent) were outright outdated and another 140 (14.6 percent) were close to becoming so. Among the Colombian priority recommendations specifically, 56.8 percent had aged past the point where their evidence base could be considered reliable, and the proportion was even higher — 62.5 percent — among the WHO guidance documents. In terms of strength, 540 recommendations (56.4 percent) were strong, 189 (19.7 percent) were weak, 173 (18.1 percent) were conditional on specific contexts, and 37 represented good-practice statements grounded in expert consensus. The overwhelming majority — 861 recommendations, or 89.9 percent — called in favor of an intervention, implying that something new must be done or added to clinical practice; only 97 recommended against a technology or service. The therapeutic landscape they covered was broad: medications were the most common target (228 recommendations), followed by therapeutic procedures (155), counseling and education (138), and diagnostic tests or procedures (119). Maternal and child health, chronic noncommunicable diseases, cancer care, and sexual and reproductive health dominated the subject matter.

The heart of the study, however, lies in its second analytical layer: determining which recommendations cannot be implemented without changing the architecture of the health system itself. Two researchers independently assessed every recommendation against the Cochrane Effective Practice and Organisation of Care (EPOC) taxonomy, a comprehensive classification framework originally developed for systematic reviews that distinguishes interventions across four domains — delivery arrangements, financial arrangements, governance arrangements, and implementation strategies. The team deliberately excluded the implementation-strategies domain, which addresses individual and institutional behavior change, and focused on the three system-level dimensions. For medications and devices, the researchers cross-checked two Colombian government databases to determine whether the product was approved by the national regulatory agency INVIMA and whether it was publicly funded. For WHO recommendations, experienced assessors judged whether each had been implemented completely, partially, or not at all in Colombia, based on review of existing national plans and programs. The classification was verified by additional team members and finalized through consensus meetings.

The verdict: 518 of the 958 recommendations — 54.1 percent — require a change in health system arrangements before they can be put into practice. The dominant category was delivery arrangements, implicated in 503 recommendations (52.5 percent). The most frequent specific need was availability of care, cited for 391 recommendations, followed by staff training (209), role expansion and extension of the healthcare workforce (155), and timely access to services (114). The pattern reveals a systemic paradox: many recommended technologies and services are formally approved and publicly funded on paper, yet remain physically inaccessible to large segments of the population. Diagnostic tests may be covered by insurance but offered only in capital cities with robust healthcare infrastructure, or provided by some insurance companies and not others. Seventy recommendations additionally required that care be delivered in a culturally appropriate manner, 56 of them in sexual and reproductive health — a finding heavily driven by WHO guidance on health worker roles in providing safe abortion care and post-abortion contraception.

Governance arrangements — the rules and processes governing authority and accountability — were required for 259 recommendations (27 percent). The most common governance change involved training, licensure, and scope-of-practice policies, accounting for 159 recommendations: for instance, allowing general practitioners to prescribe medications currently restricted to specialists. Another 89 recommendations hinged on completing regulatory registration with INVIMA before the relevant products could be authorized, and 22 required altering who decides what public insurance covers and what must be provided. Financial arrangements were needed for 102 recommendations (10.6 percent), and within this group, 92 involved modifying the list of covered services and products; 86 recommendations required adding an intervention to the statutory benefits plan or clarifying and communicating its public funding status, with medications alone accounting for 58 of these. Notably, nearly two-thirds of the recommendations requiring benefit-plan inclusion had been graded strong, offering policymakers a ready-made shortlist for cost-effectiveness analysis.

The study also surfaced a tier of recommendations that exceed the decision-making authority of the health ministry altogether. Forty-six WHO recommendations — drawn from guidance on safe abortion care, post-abortion contraception, self-care interventions for sexual and reproductive health, and national pharmaceutical pricing policies — would require legislative action, changes in other ministries, or navigation of constraints imposed by Colombia’s bilateral free trade agreement with the United States. Some of the abortion-related recommendations presuppose that abortion is legal in Colombia, a matter for lawmakers rather than health regulators. Equally sobering is the currency problem: among WHO recommendations, 244 of 363 — 67.2 percent — had not been implemented at all in Colombia, and more than half of all prioritized recommendations were past their evidence shelf life. The researchers flag this as an opportunity to redirect resources toward updating the guidelines most in need, noting that guideline development in Colombia mobilized substantial public investment and the research capacity of universities, hospitals, professional societies, and patient organizations.

The work responds to a well-documented global problem in knowledge translation. Prior research has shown that even high awareness and agreement among clinicians does not translate into guideline adherence, and that it can take up to 17 years for merely 14 percent of published research to reach everyday practice. What distinguishes the Colombian approach is its comprehensiveness — previous studies had examined individual guidelines or sampled guidelines across countries, but none had systematically consolidated every prioritized recommendation available for a single national health system and mapped the structural changes each demands. The team’s methodology has acknowledged limitations: the guidelines were not developed with uniform methodology, with some using GRADE and others relying on older grading schemes that measure different things, making harmonization imperfect. The researchers also chose not to appraise the quality of the guidelines themselves, reasoning that their unit of analysis was the recommendation and that guideline quality does not necessarily predict recommendation quality.

To make the findings actionable, the team built a publicly available interactive visualization tool, published in Spanish, that links the datasets of guidelines, recommendations, and extracted characteristics, allowing policymakers and stakeholders to filter recommendations by condition, age group, disease relevance, and required system change. The researchers frame this as the first step in a larger research program on evidence-informed implementation: identifying key recommendations is the prerequisite for prioritizing them and for diagnosing the health system challenges that must be resolved. The Colombian guidelines requiring the most structural changes were those for sexually transmitted infections (35 changes), heart failure (21), and juvenile idiopathic arthritis (18); on the WHO side, the guidance on health worker roles in key maternal services topped the list with 168 required changes. The next phase, the authors say, will explore how the database can support real-world prioritization and will incorporate the preferences of patients and health professionals — building on work such as Lynch and colleagues’ consumer-inclusive prioritization process for Australian stroke guidelines — to determine which of these 518 blocked recommendations should move first.

This comprehensive analysis, published in the prestigious journal Health Affairs, meticulously examined every new prescription drug approved between 2014 and 2018 across five high-income countries: the United States, Europe, Canada, Japan, and Australia. The researchers tracked the delays associated with submissions for regulatory review alongside the actual duration of the evaluation processes across these jurisdictions up through 2022. Their goal was to unravel the factors influencing approval speed and availability, especially distinguishing between drugs offering substantial therapeutic value and those providing minimal additional benefit over existing treatments.

Historically, advocates for faster drug access in the U.S. argued that its regulatory infrastructure enabled patients to receive novel therapies ahead of their counterparts abroad, contributing to better health outcomes. This study, however, reframes the debate by revealing that the FDA’s review process is only marginally—often just a few weeks or a month—faster than similar agencies in other wealthy nations. Instead, the more critical factor is when pharmaceutical companies elect to submit their applications. Drugs deemed to offer minimal therapeutic improvements—a category the study terms “low-value” medications—are often submitted for U.S. approval months or even years prior to being presented to foreign regulatory bodies, resulting in earlier and broader patient access stateside despite questionable medical benefit.

Lead author Irene Papanicolas, a professor at Brown University, emphasizes the nuance in these findings. She acknowledges that while speedy access to genuinely innovative medicines remains crucial, not all newly approved medications confer meaningful improvements in patient care. This distinction is essential for policymakers who seek to balance encouraging innovation with ensuring that healthcare spending delivers tangible value. The study found pharmaceutical companies are motivated by distinct business incentives when choosing when and where to seek regulatory authorization, especially for products that may struggle to gain favorable pricing or reimbursement internationally.

The divergent regulatory landscapes underscore these corporate strategies. The U.S. market, being the largest globally, allows manufacturers considerable freedom to set drug prices upon launch without mandatory health cost assessments. Contrastingly, health authorities in Canada, Europe, Japan, and Australia rigorously evaluate a drug’s therapeutic incremental benefit relative to existing alternatives—a process that heavily influences price negotiations and coverage decisions. Olivier Wouters, co-author and associate professor at Brown, explains that this regulatory rigor abroad likely spurs companies to prioritize U.S. submissions for lower-value drugs where pricing and reimbursement hurdles are comparatively lighter.

Intriguingly, the analysis also demonstrates that for drugs with clear, demonstrable clinical advantages over current standards of care, pharmaceutical companies typically synchronize submissions across all major markets, thereby equalizing the timing of approvals. In these instances, the FDA’s reviews proceed slightly faster but not to an extent that would justify attributing the U.S.’s overall drug access lead to regulatory expediency alone. This suggests a more collaborative global approach for introducing high-impact medications, contrasting sharply with the staggered U.S.-first approach for lower-value products.

These insights bear significant implications for ongoing policy debates in Washington, notably surrounding proposals such as the “most favored nation” rule, which aims to tether U.S. drug prices to those negotiated by peer countries. Papanicolas cautions that implementing such policies is fraught with complexities, especially considering the opaque nature of international drug availability and submission timing. She raises critical questions about the handling of products not yet introduced abroad and the potential unintended consequences for pharmaceutical companies’ global approval strategies, which could, paradoxically, delay patient access or distort market behaviors.

The study’s revelations resonate profoundly in the broader context of America’s disproportionate prescription drug spending, which far surpasses that of other high-income nations without consistently correlating to superior health outcomes. By demonstrating that earlier U.S. access predominantly favors medications with limited additional medical benefit, the research challenges simplistic narratives that regulatory responsiveness alone drives innovation uptake and expenditure patterns. Instead, it highlights the strategic interplay between market incentives, regulatory frameworks, and clinical value assessments that collectively shape drug availability.

Moreover, these findings invite a more discerning public dialogue on pharmaceutical pricing reform, emphasizing the importance of aligning drug approval timing and pricing strategies with the true therapeutic value offered. The nuanced picture painted by this research calls for policies that incentivize the timely introduction of transformative medicines while scrutinizing and potentially restraining expedited U.S. access to high-cost, low-value drugs that contribute disproportionately to healthcare inflation.

The Brown University-led study also exemplifies the critical role of health services research in dissecting complex systems and informing evidence-based policymaking. By integrating cross-country regulatory data with drug characteristic analyses, the research provides a sophisticated lens through which stakeholders can evaluate the multifaceted drivers of drug market dynamics and formulate interventions that optimize patient outcomes and system sustainability.

Ultimately, this investigation reframes longstanding assumptions regarding drug approval timelines and market strategies. It portrays a pharmaceutical landscape in which the nominal speed of U.S. government review is less determinative of drug availability than the strategic submission decisions by companies navigating disparate international regulatory terrains. These insights bear profound implications as the U.S. confronts mounting pressures to enhance prescription drug affordability, access, and value in an era characterized by rapid biomedical innovation and complex global health economics.

Subject of Research: International comparison of drug approval submission timing and review durations among the FDA and four international regulatory agencies, with an emphasis on therapeutic value differentiation.

Article Title: Review Times For New Drugs And Submission Delays Among The FDA And 4 International Regulators, 2014–22

News Publication Date: 2-Feb-2026

Web References:

• Health Affairs article: https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2025.00595

References:

• Papanicolas, I., Wouters, O., Sawaya, T., et al. (2026). Review Times For New Drugs And Submission Delays Among The FDA And 4 International Regulators, 2014–22. Health Affairs. DOI: 10.1377/hlthaff.2025.00595

Keywords: Pharmaceuticals, Drug Costs, Pharmaceutical Industry, Prescription Drug Prices, Drug Approval, Regulatory Review, Therapeutic Value, FDA, International Drug Markets, Health Policy, Drug Pricing Reform.

What stands out in the research is its multidimensional approach, which juxtaposes diverse country contexts against a unifying theme: the rights relating to sexual and reproductive health. By synthesizing data from different regions, the authors expose the disparities and commonalities that characterize health care delivery in relation to SRHR. This synthesis facilitates a broader understanding of how cultural, economic, and political landscapes influence the accessibility and quality of health care. The findings underscore the pressing need for policymakers to not only recognize these differences but also to appreciate how they can inform better health care strategies that are both inclusive and equitable.

One of the most striking aspects of this analysis is its emphasis on the lived experiences of individuals affected by health policies. Through qualitative methodologies intertwined with quantitative data, the researchers bring forth personal narratives that illustrate the real-world impact of health care systems on sexual and reproductive rights. These stories serve to humanize statistics, providing a face to the often abstract discussions surrounding health policy. They present vivid evidence of how inadequate health services can lead to devastating outcomes, revealing a crucial point: that policy decisions can literally be a matter of life and death.

Moreover, the article identifies key barriers that impede the realization of SRHR in various contexts. From restrictive legal frameworks to socio-cultural stigmas, the authors meticulously outline the challenges that remain prevalent. These obstacles not only hinder access to essential services but also perpetuate inequalities that predominantly affect marginalized groups, including women and LGBTQ+ individuals. The insights gleaned from this analysis are not merely theoretical; they are grounded in the harsh realities faced by many, thereby demanding urgent and actionable responses from governments and health organizations alike.

The intersectionality of gender, race, and economic status emerges as a central theme throughout the research. The authors argue that a one-size-fits-all approach to health care policy is inadequate. Instead, tailored strategies that account for the specific needs of diverse groups within populations are necessary. This perspective aligns with contemporary discussions in public health about the importance of intersectionality, emphasizing that effective health care must be responsive to the nuanced challenges faced by different demographics.

In light of the COVID-19 pandemic, the importance of resilient health care systems has never been more pronounced. The article posits that the crisis has exposed vulnerabilities in existing infrastructures, particularly concerning SRHR. As health systems grapple with recovery and renewal post-pandemic, the researchers advocate for integrating lessons learned into future policy designs. By prioritizing sexual and reproductive health within the context of broader health initiatives, countries can better position themselves to withstand future shocks.

Furthermore, the review highlights successful case studies that exemplify positive policy changes. These examples serve as blueprints, showcasing initiatives that have effectively enhanced SRHR across different settings. By analyzing what has worked in various contexts, the authors provide evidence-based recommendations that can be adapted and implemented within diverse health care systems. This optimistic angle fosters hope and encourages policymakers to pursue innovative solutions that are grounded in reality.

At a global level, the study places significant emphasis on the role of international organizations in promoting SRHR. The authors argue that collaboration among nations and adherence to international human rights frameworks are paramount to advancing health care objectives. The synthesis of these country case studies provides a robust platform for advocating for global solidarity in addressing SRHR. As health issues transcend borders, global cooperation becomes essential for sustaining progress and equity in health care.

The implications of this research extend beyond academic discourse; they resonate with public health advocates, NGOs, and community organizations striving for change. As stakeholders navigate the complexities of health care policies, the insights presented in the article can empower them with knowledge to engage more effectively with policymakers. By leveraging data-driven narratives and fostering dialogue, advocates can be catalysts for necessary reforms.

Moreover, the notion of sustainability is intricately woven into the analysis. The authors stress that health care systems must evolve not only to meet present needs but also to anticipate future challenges. This forward-looking perspective encapsulates the essence of public health: a commitment to ensuring that health care is not merely reactive but proactive. By embedding sustainability into health care policies, nations can cultivate resilient systems equipped to address emerging health threats.

The rigorous methodology employed in this study adds credibility to its findings. The authors utilized a multi-method approach, combining quantitative analysis with qualitative insights, thereby enriching their exploration of SRHR. This methodological rigor exemplifies the importance of interdisciplinary research in addressing complex global health issues, showcasing how diverse perspectives can illuminate the multifaceted nature of health care delivery.

In conclusion, the article by Barbazza and colleagues serves as a clarion call for renewed commitment to sexual and reproductive health and rights within primary health care. By synthesizing 52 diverse case studies, the authors have created a rich tapestry of knowledge, illuminating not just difficulties but also successful strategies that can be adopted worldwide. Their work lays a foundation for future research and evidence-based policymaking, stressing the urgency of addressing SRHR at the nexus of health care systems. As the world navigates the post-pandemic landscape, the insights from this analysis will undeniably serve as a critical resource for health policymakers and advocates alike, pushing the agenda for a healthier and more equitable future for all.

Subject of Research: Sexual and Reproductive Health and Rights in Primary Health Care

Article Title: Policy-oriented analysis of primary health care country case studies: multi-country synthesis of 52 cases through a sexual and reproductive health and rights lens.

Article References:

Barbazza, E., Frenette, N., Rouleau, K.D. et al. Policy-oriented analysis of primary health care country case studies: multi-country synthesis of 52 cases through a sexual and reproductive health and rights lens. BMC Health Serv Res (2026). https://doi.org/10.1186/s12913-026-14051-x

Image Credits: AI Generated

DOI: 10.1186/s12913-026-14051-x

Keywords: Sexual Health, Reproductive Rights, Health Policy, Global Health, Primary Health Care, Case Studies, International Cooperation, Equity in Health, Sustainable Health Systems.

However, these protections now face a profound legal jeopardy stemming from the Supreme Court’s decision to hear Kennedy v. Braidwood Management Inc. on April 21. This pivotal case scrutinizes the constitutionality of the ACA’s preventive services requirement, specifically challenging the mandate that private insurers cover services recommended by the U.S. Preventive Services Task Force (USPSTF). The underlying constitutional contention arises from claims that USPSTF members—unconfirmed by the President and Senate—violate the Appointments Clause, thus rendering the preventive mandate unconstitutional.

The ACA’s preventive services mandate represents a paradigm shift in U.S. health policy by removing financial obstacles to screenings and preventive medications. It encompasses a spectrum of services from blood pressure and cholesterol assessments to critical screenings for various cancers, including breast, cervical, colorectal, and lung cancers, as well as infectious diseases like HIV and hepatitis C. The USPSTF’s role is pivotal because their recommendations are grounded in rigorous evidence synthesis demonstrating substantial health improvements via early detection and prevention.

To elucidate the real-world scope of this mandate, the Stanford-Harvard research collaboration analyzed claims data covering over 130 million privately insured individuals, with a detailed focus on a representative cohort of 16.1 million enrollees drawn from the MarketScan database. The investigators identified ten services particularly vulnerable to the potential disruption of the Braidwood case, including recent USPSTF recommendations that expanded prevention options such as statin therapy for cardiovascular risk reduction and pre-exposure prophylaxis (PrEP) for HIV prevention.

Among the critical insights, the study found that almost half of privately insured women access at least one of these preventive services without cost. Moreover, thirteen states each have over one million individuals benefiting from these no-cost services, with Texas—where the legal challenge originated—accounting for three million recipients alone. Such regional analyses highlight the geographic breadth and policy significance of the preventive mandate across the nation’s healthcare landscape.

The potential erosion of mandated preventive coverage carries serious public health implications. Accessible preventive care substantially mitigates progression of chronic diseases, reduces hospitalizations, and lowers long-term healthcare expenditures. The Stanford team emphasizes that dismantling these protections could destabilize decades of progress in public health, reversing gains in early cancer detection, infectious disease control, and cardiovascular disease prevention.

Underlying the constitutional debate is the nuance that the USPSTF operates as an independent panel of experts appointed by the Director of the Agency for Healthcare Research and Quality, not by elected officials, which plaintiffs argue conflicts with constitutional appointment processes. Additionally, challengers have claimed that the mandate infringes upon religious liberties, particularly concerning coverage for HIV preventive medication, adding layers of complexity to the Supreme Court’s impending evaluation.

This inquiry coincides with prior studies estimating that as many as 150 million people could be eligible for no-cost preventive services based on employer-sponsored insurance coverage. Prior analyses, focusing on narrower subsets of preventive care, suggested that up to 10 million individuals utilized these services free of charge. The current study’s broader and more granular approach offers a definitive assessment of the mandate’s reach, contextualizing millions of beneficiaries within the ongoing legal discourse.

At the heart of this research is a recognition that preventive health services underpin a sustainable and equitable healthcare system. By facilitating early intervention without financial impediments, the ACA’s mandate enhances population health outcomes and reduces disparities rooted in socioeconomic status. The research team notes the mandate’s robust popularity in public opinion polls, reflecting societal consensus on the intrinsic value of preventive healthcare.

As the Supreme Court deliberates, millions of Americans stand at a crossroads where the future of guaranteed no-cost preventive services hangs in the balance. The decision in Kennedy v. Braidwood will not only shape healthcare policy but also signal the federal government’s commitment to evidence-based preventive medicine. Researchers involved in the study appeal for recognition of the mandate’s proven benefits and warn against unintended consequences of judicial invalidation.

The collaborative efforts of health policy experts from Stanford and Harvard showcase the power of rigorous data analysis to inform legal and policy debates. The study authors—led by Michelle Bronsard, MSc, alongside Joshua Salomon, PhD, and other eminent colleagues—stress the importance of maintaining policy frameworks that align medical recommendations with insurance coverage structures, thereby safeguarding public health achievements.

Ultimately, the unfolding legal challenge embodies a critical intersection of constitutional law, health policy, and population health science. The ramifications extend beyond insurance companies and courts to the very individuals who rely upon these preventive measures for early detection and disease prevention. This case exemplifies the contentious yet vital dialogue between governmental authority, expert advisory processes, and the lived health realities of millions in the United States.

Subject of Research: The utilization and legal challenges of no-cost preventive health services mandated under the Affordable Care Act (ACA), focusing on the impact of the Kennedy v. Braidwood case.

Article Title: Use of No-Cost Preventive Services Jeopardized by Kennedy v Braidwood

News Publication Date: 17-Apr-2025

Web References:

• Stanford Prevention Policy Modeling Lab: https://ppml.stanford.edu/
• Kennedy v. Braidwood case brief: https://www.kff.org/womens-health-policy/issue-brief/explaining-litigation-challenging-the-acas-preventive-services-requirements-braidwood-management-inc-v-becerra/
• JAMA Health Forum article: https://jamanetwork.com/journals/jama-health-forum/fullarticle/2832980
• ACA preventive care background (CMS): https://www.cms.gov/cciio/resources/fact-sheets-and-faqs/preventive-care-background
• MarketScan database: https://www.merative.com/documents/merative-marketscan-research-databases

References:
Bronsard, M., Sabety, A., Rönn, M., Swartwood, N. A., & Salomon, J. (2025). Use of No-Cost Preventive Services Jeopardized by Kennedy v Braidwood. JAMA Health Forum. DOI: 10.1001/jamahealthforum.2025.1559

Keywords: Public health; Health care; Health care policy; Health care delivery; Health care costs